ABSTRACT
This chapter is supposed to focus on potential stem cell therapies for Parkinson’s disease (PD). Since there have been only a few such encouraging stem cell studies in animal models of the disease, the preclinical studies are likewise short in number, and, furthermore, there is perhaps only one human PD patient transplanted to date with human stem or progenitor cells, this chapter will instead concentrate on the new field of regenerative medicine as a target for stem cell biology to help translate new approaches for both protecting and replacing the compromised dopaminergic nigrostriatal pathway.
